Clinical trialsCompany release

Aptevo says refined priming doses cut infusion reactions with mipletamig in frontline AML

🇺🇸 Aptevo Therapeutics Inc. (APVO) · Thu 05 Nov 2026

Aptevo reports that successive changes to mipletamig's priming-dose regimen have substantially lowered infusion-related reactions in the RAINIER study, with Phase 2 planned for 2027.

Aptevo Therapeutics announced on 5 November 2026 that successive refinements to the priming-dose regimen of its drug mipletamig have substantially reduced infusion-related reactions in the ongoing RAINIER study.

In the study, mipletamig is given together with venetoclax and azacitidine to patients with newly diagnosed acute myeloid leukaemia (AML) who are unfit for intensive chemotherapy. The company ties the dosing work to its discussions with the US Food and Drug Administration (FDA).

Aptevo expects to complete RAINIER by the end of 2026 and plans to begin a Phase 2 study in 2027. Data from RAINIER are due at the American Society of Hematology (ASH) meeting in December.

The announcement does not, in the information available, include figures on reaction rates, patient numbers or the specific dose changes, so the size of the improvement cannot yet be independently assessed.

What it means for your team

  • Infusion-related reactions are a key tolerability issue for this drug, and the priming-dose schedule is the company's main tool for addressing them.
  • Regulatory teams should watch for the ASH data in December to see the actual reaction rates and the final dosing regimen carried into Phase 2.
  • Pharmacovigilance and clinical safety teams in comparable programmes may find the dose-refinement approach, discussed with the FDA, a useful reference point once details are published.
  • No quantitative evidence has been released yet, so the claim of a substantial reduction remains unverified.

Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗

Article written by VigiEye from the official source (Aptevo Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →